275 related articles for article (PubMed ID: 7517229)
1. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
[TBL] [Abstract][Full Text] [Related]
2. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival and nearly asymptomatic course of carcinoid tumour with multiple metastases (treated by surgery, chemotherapy, (90)Y-DOTATATE, and LAR octreotide analogue): a case report.
Kałuzny M; Bolanowski M; Sukiennik-Kujawa M; Ponikowski P; Handkiewicz-Junak D; Jarzab B; Jawiarczyk A; Syrycka J
Endokrynol Pol; 2009; 60(5):401-6. PubMed ID: 19885812
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
5. Carcinoid crisis after biopsy of a bronchial carcinoid.
Karmy-Jones R; Vallières E
Ann Thorac Surg; 1993 Dec; 56(6):1403-5. PubMed ID: 8267450
[TBL] [Abstract][Full Text] [Related]
6. Management of disseminated midgut carcinoid tumours.
Ahlman H; Wängberg B; Jansson S; Stenqvist O; Geterud K; Tylén U; Caidahl K; Scherstén T; Tisell LE
Digestion; 1991; 49(2):78-96. PubMed ID: 1724766
[TBL] [Abstract][Full Text] [Related]
7. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O
Eur J Cardiothorac Surg; 2002 May; 21(5):913-7. PubMed ID: 12062286
[TBL] [Abstract][Full Text] [Related]
9. Primary hepatic carcinoid tumor with carcinoid syndrome and carcinoid heart disease: a case report of a patient on long-term follow-up.
Tohyama T; Matsui K; Kitagawa K
Intern Med; 2005 Sep; 44(9):958-62. PubMed ID: 16258211
[TBL] [Abstract][Full Text] [Related]
10. Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
Seymour N; Sawh SC
Can J Anaesth; 2013 May; 60(5):492-9. PubMed ID: 23328959
[TBL] [Abstract][Full Text] [Related]
11. [Analogs of somatostatin and carcinoid tumors].
Gutiérrez Rodero F; Morales Cano JM; de Blas Laborda C; González Barber A
Med Clin (Barc); 1990 Jun; 95(2):78-9. PubMed ID: 2250512
[No Abstract] [Full Text] [Related]
12. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
Davì MV; Bodei L; Francia G; Bartolomei M; Oliani C; Scilanga L; Reghellin D; Falconi M; Paganelli G; Lo Cascio V; Ferdeghini M
J Endocrinol Invest; 2006 Jun; 29(6):563-7. PubMed ID: 16840837
[TBL] [Abstract][Full Text] [Related]
13. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide.
Joensuu H; Kätkä K; Kujari H
Acta Endocrinol (Copenh); 1992 Feb; 126(2):184-5. PubMed ID: 1371898
[TBL] [Abstract][Full Text] [Related]
14. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of combined cyclophosphamide and methotrexate therapy in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome.
Moertel CG; O'Connell MJ; Reitemeier RJ; Rubin J
Cancer Treat Rep; 1984 Apr; 68(4):665-7. PubMed ID: 6201271
[TBL] [Abstract][Full Text] [Related]
17. [Enteral hyperoxalosis due to therapy with a somatostatin analog].
Ranft K; Eibl-Eibesfeldt B
Dtsch Med Wochenschr; 1990 Feb; 115(5):179-81. PubMed ID: 2298134
[TBL] [Abstract][Full Text] [Related]
18. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
Alberts AS; Falkson G
S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of carcinoid syndrome with a somatostatin analogue].
Döbrönte Z; Stöckert A; Végh G; Varga L
Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
[TBL] [Abstract][Full Text] [Related]
20. Octreotide as a rapid and effective painkiller for metastatic carcinoid tumor.
Katai M; Sakurai A; Inaba H; Ikeo Y; Yamauchi K; Hashizume K
Endocr J; 2005 Apr; 52(2):277-80. PubMed ID: 15863961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]